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Abstract  32 
An integral part of the antiviral innate immune response is the APOBEC3 family of single-stranded DNA 33 
cytosine deaminases, which inhibits virus replication through deamination-dependent and -independent 34 
activities. Viruses have evolved mechanisms to counteract these enzymes such as HIV-1 Vif-mediated 35 
formation of a ubiquitin ligase to degrade virus-restrictive APOBEC3 enzymes. A new example is 36 
Epstein-Barr virus (EBV) ribonucleotide reductase (RNR)-mediated inhibition of cellular APOBEC3B 37 
(A3B). The large subunit of the viral RNR, BORF2, causes A3B relocalization from the nucleus to 38 
cytoplasmic bodies and thereby protects viral DNA during lytic replication. Here, we use 39 
co-immunoprecipitation and immunofluorescent microscopy approaches to ask whether this APOBEC 40 
neutralization mechanism is shared with the -herpesvirus Kaposi’s sarcoma-associated herpesvirus 41 
(KSHV) and the α-herpesvirus, herpes simplex virus-1 (HSV-1). The large RNR subunit of KSHV, 42 
ORF61, co-precipitated multiple APOBEC3s including A3B and APOBEC3A (A3A). KSHV ORF61 also 43 
caused relocalization of these two enzymes to perinuclear bodies (A3B) and to oblong cytoplasmic 44 
structures (A3A). The large RNR subunit of HSV-1, ICP6, also co-precipitated A3B and A3A and was 45 
alone sufficient to promote the relocalization of these enzymes from nuclear to cytoplasmic 46 
compartments. HSV-1 infection caused similar relocalization phenotypes, and this was fully dependent on 47 
ICP6. These relocalization phenotypes could be exacerbated by infection with viruses that overexpress 48 
ICP6 due to an ICP4 deletion. These results combine to indicate that both - and α-herpesviruses 49 
counteract the antiviral activities of cellular APOBEC3 enzymes through a similar RNR-dependent 50 




The APOBEC3 family of DNA cytosine deaminases constitutes a vital innate immune defense against a 55 
range of different viruses. A novel counter-restriction mechanism has recently been uncovered for the 56 
γ-herpesvirus EBV, in which a subunit of the viral protein known to produce DNA building blocks 57 
(ribonucleotide reductase) causes APOBEC3B to relocalize from the nucleus to the cytosol. Here, we 58 
extend these observations to a closely related γ-herpesvirus, KSHV, and to a more distantly related 59 
-herpesvirus, HSV-1. Relocalization was also evident for these ribonucleotide reductases and 60 
APOBEC3A, which is 92% identical to APOBEC3B. These studies are important because they suggest a 61 
conserved mechanism of APOBEC3 evasion by large double-stranded DNA herpesviruses. Strategies to 62 
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Introduction 67 
There are nine described human herpesviruses (HHV-1 to -8, including HHV6A and 6B), each of 68 
which is capable of establishing a lifelong infection [1]. They are among the most prevalent viruses with 69 
some such as Epstein-Barr virus (EBV/HHV-4) exceeding 90% seroprevalence in the global population 70 
[2]. Primary infection by herpesviruses is often accompanied by mild clinical symptoms and is generally 71 
self-limiting before progressing into latency, where the virus persists asymptomatically and is capable of 72 
periodic cycles of reactivation [3]. A classic example is herpes simplex virus-1 (HSV-1/HHV-1) 73 
infection, which produces primary vesicular lesions in the oral mucosa and establishes latency in adjacent 74 
neural ganglia where reactivation of the virus leads to formation of repeated lesions in the same area over 75 
the course of the infected individual’s life [4-6]. Other herpesviruses such as human cytomegalovirus 76 
(HCMV/HHV-5) and Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) establish latency in 77 
various myeloid and lymphoid compartments, often without symptoms associated with reactivation 78 
except in the cases of immunosuppression such as organ transplantation or untreated HIV-1 infection [7-79 
13].  80 
Overcoming or evading immune surveillance is critical to the survival of human herpesviruses, 81 
and these viruses utilize a diverse complement of immunoevasive proteins and RNAs to establish 82 
life-long infections [14]. An important arm of the innate immune response lies in the APOBEC family of 83 
single-stranded DNA cytosine deaminases [15-17]. Each of the seven APOBEC3 (A3) enzymes, A3A-D 84 
and A3F-H, have been implicated in the restriction and hypermutation of a variety of different viruses 85 
including lentiviruses (HIV-1, HIV-2, HTLV-1) [18-22], hepadnaviruses (HBV) [23, 24], endogenous 86 
retroviruses (LINE-1, Alu) [25, 26], small DNA tumor viruses (HPV, JC/BK-PyV) [27-31], and most 87 
recently EBV [32, 33]. It is difficult, if not impossible, to predict a priori which subset of APOBEC3 88 
enzymes has the potential to engage a given virus and, furthermore, how that virus might counteract 89 
potentially restrictive A3 enzymes. 90 
Each of the three herpesvirus subfamilies (α, β, and γ) encode both large and small RNR subunits 91 
with the exception of β-herpesviruses, which lack a small subunit (Fig 1A). These RNRs have the 92 
canonical function of synthesizing deoxyribonucleotides by reducing the 2’-hydroxyl from ribonucleotide 93 
substrates [34]. While they are essential for all cellular life, the requirement for endogenous viral RNRs 94 
differs tremendously across viral families. For example, RNRs are almost ubiquitous among large 95 
double-stranded DNA (dsDNA) viruses, such as herpesviruses, poxviruses, and tailed phages 96 
(caudovirales), presumably due to high dNTP requirements during DNA replication [35-37]. On the other 97 
hand, most small dsDNA viruses and single-stranded DNA viruses do not encode RNRs and instead rely 98 
on host-encoded RNRs for deoxyribonucleotide production [38, 39]. In addition to ribonucleotide 99 
reductase activity, some viral RNRs have been shown to engage in non-catalytic activities that result in 100 
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proviral phenotypes. For instance, the HSV-1 and HSV-2 large ribonucleotide reductase subunits, ICP6 101 
and ICP10, respectively, have unique N-terminal extensions that block caspase-8 activity to inhibit 102 
apoptosis and bind RIP3 to promote necroptosis  [40-43] (Fig 1B). Interestingly, HCMV UL45 also has 103 
anti-apoptotic and pro-necroptotic functions despite lacking a viral small subunit counterpart, suggesting 104 
that the primary function of this RNR large subunit is no longer ribonucleotide reduction [43-45].  105 
Recently, we identified the ribonucleotide reductase (RNR) large subunit of the γ-herpesvirus 106 
EBV as novel inhibitor of APOBEC3B (A3B) [32]. We found that EBV BORF2 functions by directly 107 
binding A3B and relocalizing it from the nucleus to the cytoplasmic compartment, which prevents 108 
A3B-mediated deamination of cytosines to uracils in viral genomic DNA during lytic replication. In the 109 
absence of BORF2, we found that A3B was able to mutate EBV genomes and reduce viral titers and 110 
infectivity. We also reported that the homologous protein from KSHV, ORF61, is similarly capable of 111 
A3B co-immunoprecipitation and relocalization [32]. Here, we ask whether this novel virus protection 112 
mechanism is specific or more general-acting by assessing interactions between -herpesvirus 113 
BORF2/ORF61 and other human APOBEC3 enzymes and by determining whether the more distantly 114 
related -herpesvirus HSV-1 has a similar A3 neutralization mechanism. We found that, in addition to 115 
binding and relocalizing A3B, both BORF2 and ORF61 were also capable of co-immunoprecipitation and 116 
relocalization of A3A. More importantly, we found that the HSV-1 RNR large subunit ICP6 similarly 117 
binds and relocalizes both A3B and A3A. Overexpression studies showed that ICP6 alone is sufficient for 118 
A3B and A3A relocalization. Infection studies with mutants demonstrated that ICP6 is essential and that 119 
no other viral protein is capable of this function. These data combined to indicate that pathogenic  and -120 
herpesviruses have evolved an effective APOBEC3 counteraction mechanism, which is governed by the 121 
viral RNR large subunit. 122 
 123 
Results 124 
EBV BORF2 and KSHV ORF61 bind and relocalize both A3B and A3A 125 
Our prior co-immunoprecipitation (co-IP) experiments indicated that EBV BORF2 interacts 126 
strongly with A3B and weakly with A3A and A3F (see Fig. 1c in Cheng et al. [32]). EBV BORF2 was 127 
both necessary and sufficient to relocalize A3B in a variety of different cell types including endogenous 128 
A3B in the AGS gastric carcinoma cell line and the M81 B cell line [32]. However, our original studies 129 
did not address whether EBV BORF2 could functionally interact with and relocalize any of these related 130 
human A3 enzymes. We therefore performed immunofluorescent (IF) microscopy studies of U2OS cells 131 
overexpressing A3-mCherry constructs with either empty vector or BORF2-FLAG. As reported, A3B is 132 
nuclear, A3A has a cell-wide localization, A3H is cytoplasmic and nucleolar, and the other A3s are 133 
cytoplasmic [46-50]. Also as expected, BORF2 caused a robust and complete relocalization of nuclear 134 
 6 
A3B to perinuclear aggregates (Fig 2). Interestingly, BORF2 co-expression with A3A led to the presence 135 
of novel linear elongated structures concomitant with normal A3A localization. The localization patterns 136 
of the other five A3s were unchanged by BORF2 co-expression. Small BORF2 punctate structures were 137 
also noted in all conditions including the mCherry control, which is likely due to transfected BORF2 138 
interacting with endogenous A3B (previously shown to be elevated in U2OS [32]). Similar A3B and A3A 139 
relocalization patterns were evident in Vero cells except that A3A relocalization became whole-cell 140 
without elongated structures (Supplementary Fig 1). 141 
Like EBV BORF2, KSHV ORF61 was also shown to co-IP and relocalize A3B [32]. However, 142 
our original studies did not examine the specificity of this interaction by comparing with related human 143 
A3 enzymes. We therefore used co-IP experiments to evaluate KSHV ORF61 interactions with a full 144 
panel of human A3 enzymes. ORF61-FLAG was co-expressed with A3-HA family members in 293T 145 
cells, subjected to anti-FLAG affinity purification, and analyzed by immunoblotting (Fig 3A). The 146 
ORF61-FLAG pulldown resulted in A3B recovery as described [32]. However, the ORF61-FLAG IP also 147 
yielded a robust interaction with A3A and weaker interactions with A3D and A3F.  148 
These KSHV ORF61-A3 interactions were then evaluated by IF microscopy experiments to look 149 
for changes in A3 localization in U2OS and Vero cells (Fig 3B). As expected [32], KSHV ORF61 caused 150 
A3B to relocalize to perinuclear aggregates. Moreover, as above for BORF2 and A3A, ORF61 151 
co-expression caused a portion of the cellular A3A to localize to intense elongated linear structures in the 152 
cytosolic compartment (Fig 3B). No other A3 proteins showed altered subcellular localization in these 153 
experiments. These new results with EBV BORF2 and KSHV ORF61 combined to indicate that both 154 
A3B and A3A may be cellular targets of viral RNR-mediated neutralization.  155 
 156 
HSV-1 ICP6 binds and relocalizes A3B and A3A 157 
 To test whether RNR-mediated APOBEC antagonism is a more broadly conserved mechanism, a 158 
series of co-IP experiments was done with the large RNR subunit of HSV-1, ICP6. FLAG-ICP6 was 159 
co-expressed with each of the seven different HA-tagged human A3s in 293T cells and subjected to 160 
anti-FLAG IP as above. The EBV BORF2-A3B interaction was used as a positive control and BORF2-161 
A3G as a negative control to be able to compare the relative strengths of pulldowns between RNRs and 162 
A3s. HSV-1 ICP6 showed a strong interaction with A3A and weaker, but detectable, interactions with 163 
A3B, A3C, and A3D (Fig 4A).  164 
Next, IF microscopy was used to assess functional interactions between HSV-1 ICP6 and each of 165 
the human A3 enzymes. Human U2OS osteosarcoma cells were co-transfected with mCherry-tagged A3s 166 
and either empty vector or FLAG-tagged HSV-1 ICP6 and analyzed by IF after 48 hours (Fig 4B). On its 167 
own EBV BORF2 shows a cytoplasmic distribution and, as shown previously [32], it was able to 168 
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completely relocalize A3B from the nucleus to cytoplasm. In comparison, HSV-1 FLAG-ICP6 showed a 169 
broadly cytoplasmic localization that did not change significantly with co-expression of any A3. 170 
However, co-expression of FLAG-ICP6 and A3B-mCherry or A3A-mCherry led to a near complete 171 
relocalization of these DNA deaminases from the nucleus to the cytoplasm. HSV-1 ICP6 co-expression 172 
with the other A3s did not lead to any remarkable change in localization. These results suggested that, 173 
although HSV-1 ICP6 interacted by co-IP with several A3s to varying degrees, functionally relevant 174 
interactions may only be occurring with A3B and A3A.   175 
 176 
HSV-1 infection relocalizes A3B and A3A 177 
To address whether HSV-1 infection similarly promotes relocalization of A3B and A3A, U2OS 178 
cells were transfected with A3-mCherry constructs 48 hours prior to either mock or HSV-1 infection. We 179 
used K26GFP, a HSV-1 strain that has a GFP moiety fused to capsid protein VP26 to allow for 180 
identification of infected cells [51]. Cells were analyzed by IF 8 hours post-infection (hpi) (Fig 5). Similar 181 
to the ICP6 overexpression experiments described above, HSV-1 infection caused A3A to relocalize to 182 
the cytoplasmic compartment and A3B to change from a predominantly nuclear localization to a more 183 
cell-wide distribution. A3C also changed from a predominantly cytoplasmic localization to a more diffuse 184 
whole cell distribution, whereas A3D, A3F, A3G, and A3H were unchanged by HSV-1 infection. Similar 185 
relocalization patterns were found in HeLa cells following HSV-1 K26GFP infection (Supplementary 186 
Fig 2). Moreover, time-course experiments showed that relocalization of A3A was detectable as early as 187 
3 hpi, whereas A3B and A3C relocalization became apparent by 6 or 9 hpi (Supplementary Fig 3). 188 
These kinetic differences may reflect a differential affinity of the viral protein(s) to bind to these cellular 189 
A3 enzymes and/or competitions with cellular interactors. Quantification of the mean fluorescence 190 
intensity in nuclear and cytoplasmic compartments showed that the nuclear localization of A3A and A3B 191 
was significantly decreased upon HSV-1 infection, but A3G localization remained unaltered 192 
(Supplementary Fig 4).  193 
 194 
HSV-1-mediated relocalization of A3B and A3A requires ICP6  195 
To investigate whether the HSV-1 large RNR subunit is necessary for A3A/B relocalization, we 196 
next examined A3 localization in cells following infection with an HSV-1 KOS1.1 strain lacking ICP6 197 
due to a deletion of the UL39 gene (UL39 encodes ICP6) [52]. Vero cells were transfected with 198 
A3-mCherry constructs 48 hours prior to mock infection or infection with KOS1.1 or KOS1.1ΔICP6. 199 
After 8 hours, cells were fixed, permeabilized, and subjected to IF analysis by staining for the HSV-1 200 
immediate early protein ICP27 to mark infected cells, and monitoring A3 localization through mCherry 201 
fluorescence. As above, HSV-1 infection caused the relocalization of A3A, A3B, and A3C (Fig 6A). 202 
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However, only the relocalization A3A and A3B was ICP6-dependent, whereas A3C redistributed 203 
regardless of the presence of ICP6. These results provide strong support for mechanistic conservation of 204 
the RNR large subunit-A3 interaction (A3A and A3B) and also indicated that A3C relocalization by 205 
HSV-1 is mechanistically distinct.  206 
To further investigate the role of ICP6 in mediating A3A and A3B relocalization, U2OS cells 207 
were infected with an HSV-1 KOS mutant with a deletion in the ICP4 gene [53]. ICP4, an immediate 208 
early protein, is the major transcriptional activator protein of HSV-1 [53]. ICP4-null mutants exhibit a 209 
strict block to expression of nearly all viral delayed-early and late genes, but are competent to express the 210 
viral immediate-early genes (ICP0, ICP22, UL54, and US12) as well the UL39 gene, a delayed-early gene 211 
that is uniquely transactivated by ICP0 [54]. In fact, at intermediate and late times post-infection, 212 
ICP4-null mutants express abnormally high levels of both the immediate early proteins and ICP6 [53]. 213 
Similar to what was seen for wild-type HSV-1 infection, infection with the HSV-1 KOS∆ICP4 mutant 214 
also led to A3A and A3B relocalization, but with noticeably more pronounced phenotypes (Fig 6B). For 215 
instance, this mutant virus caused A3B-mCherry to form perinuclear aggregates reminiscent of previously 216 
observed BORF2-A3B bodies [32] (Fig 6B). Interestingly, A3C localization remained predominantly 217 
nuclear upon HSV-1 KOSΔICP4 infection, suggesting that one of the other four immediate early proteins 218 
besides ICP4 induces its relocalization. Taken together, these data show that HSV-1 ICP6 is both 219 
necessary and sufficient for the relocalization of A3A and A3B, and that at least one other viral factor is 220 




 We previously described a novel mechanism of A3B counteraction by γ-herpesvirus RNR large 225 
subunits, EBV BORF2 and KSHV ORF61 [32]. These viral proteins interact directly with A3B, relocalize 226 
it from the nuclear to the cytoplasmic compartment, and protect lytically replicating viral genomes from 227 
A3B-mediated deamination and hypermutation. Here, we investigated the question of specificity by 228 
comparing interactions with the full repertoire of seven different human A3 enzymes, and we also 229 
addressed the potential for broader conservation by asking whether the α-herpesvirus HSV-1 has a similar 230 
APOBEC3 counterdefense mechanism. Although EBV BORF2 and KSHV ORF61 were able to interact 231 
with several different A3 proteins in co-IP experiments, these viral RNR large subunits only promoted the 232 
relocalization of A3B and A3A. HSV-1 ICP6 showed a similar range of co-IP interactions and also only 233 
promoted the relocalization of A3B and A3A. Wild-type but not ICP6 deletion mutant HSV-1 infections 234 
yielded similar A3B and A3A relocalization phenotypes. These studies combine to indicate that human - 235 
and -herpesviruses possess a conserved A3B/A counterdefense .  236 
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 The question of whether A3B, A3A, or both enzymes are most relevant to herpesvirus 237 
pathogenesis is likely to vary among herpesvirus type and depend, at least in part, on the complex 238 
interplay between viral tropism(s) and alternating modes of latent versus lytic replication. For EBV, 239 
epithelial cells serve as the source of primary infection which are mandatory for establishing lytic 240 
replication cycles  for person-to-person spread and enabling secondary infection of B lymphocytes for 241 
establishment of long-term latency [55]. B cells also support lytic reactivation for reinfection and 242 
maintenance of EBV in the blood [56]. Here, A3B may be more important than A3A simply because its 243 
expression is well-documented in these cell types [57, 58]. Likewise, KSHV infects epithelial and B cells, 244 
but also engages in infection of clinically relevant endothelial cells which can lead to Kaposi’s sarcoma 245 
[59]. Additionally, monocytes are likely to be a secondary reservoir of latent infection in addition to the B 246 
cell reservoir [60-62]. It would therefore not be surprising that KSHV requires the capacity to relocalize 247 
both A3B and A3A (A3B neutralization for replication in B cells and A3A neutralization for replication 248 
in monocytes/macrophages, where A3A can be expressed at extremely high levels) [57, 63, 64]. For 249 
HSV-1, although neither A3B nor A3A expression has been reported in neural/CNS cells, lytic replication 250 
in epithelial cells may require functional neutralization of A3B and/or A3A [65, 66]. Of course, dedicated 251 
functional studies in the most disease relevant in vivo systems will be required to fully address the 252 
question of whether A3B, A3A, or both enzymes are most relevant to herpesvirus pathogenesis.  253 
Additional studies will also be required to determine if the β-herpesviruses are also able to 254 
counteract the activities of APOBEC3 enzymes. Preliminary studies using the HCMV homologue, UL45, 255 
showed no detection of interaction with A3B or A3A by co-IP (data not shown), although this alone does 256 
not rule-out the absence of an A3 counteraction mechanism. The fact that all herpesviruses analyzed thus 257 
far have an ability to relocalize A3B and A3A strongly suggests that these enzymes pose a significant 258 
threat to the genetic integrity of these pathogens. Indeed, our prior studies showed that A3B causes 259 
declines in both EBV viral titers and infectivity for viruses lacking BORF2. Given the strong mechanistic 260 
conservation demonstrated here, we anticipate even larger virus replication phenotypes for RNR mutants 261 
in relevant in vivo systems. However, such studies will require a structural understanding of the A3-RNR 262 
interactions such that separation-of-function mutants can be engineered to dissociate phenotypes due to 263 
A3 enzymes and those due to RNR activity as well as other important alternative functions.  264 
 265 
Materials and Methods 266 
Generation of herpesvirus phylogenetic tree. Amino acid sequences for herpesvirus ribonucleotide 267 
reductase large subunits were obtained from NCBI Protein RefSeq with the following GenBank accession 268 
numbers: HSV-1 ICP6 YP_009137114.1, HSV-2 ICP10 YP_009137191.1, VZV ORF19 NP_040142.1, 269 
EBV BORF2 YP_401655.1, HCMV UL45 YP_081503.1, HHV6A U28 NP_042921.1, HHV6B U28 270 
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NP_050209.1, HHV7 U28 YP_073768.1, KSHV ORF61 YP_001129418.1. Alignment was generated 271 
using MUSCLE: multiple sequence alignment with high accuracy and high throughput [67] and 272 
phylogenetic tree was made using a neighbor-joining tree without distance corrections. Output was made 273 
using FigTree using scaled branches [68]. 274 
DNA constructs for expression in human cell lines. The full set of pcDNA3.1(+) human APOBEC-HA 275 
expression constructs has been described [69] [A3A (GenBank accession NM_145699), A3B 276 
(NM_004900), A3C (NM_014508), A3D (NM_152426), A3F (NM_145298), A3G (NM021822), A3H 277 
(haplotype II; FJ376615)]. The full set of APOBEC-mCherry expression constructs was PCR amplified 278 
with Phusion High Fidelity DNA Polymerase (NEB M0530) from previously described A3-mCherry 279 
constructs [46] and subcloned into pcDNA5/TO (Invitrogen V103320). The forward PCR primers are as 280 
follows: A3A (5’-NNN NAA GCT TAC CAC CAT GGA AGC C-3’), A3B and A3C (5’-NNN NNA 281 
AGC TTA CCA CCA TGA ATC CA-3’), A3D (5’-NNN NNA AGC TTA CCA CCA TGA ATC CA-3’), 282 
A3F (5’-NNN NNA AGC TTA CCA CCA TGA AGC CT-3’), A3G (5’-NNN NAA GCT TAC CAC 283 
CAT GAA GCC T-3’), and A3H (5’-NNN NAA GCT TAC CAC CAT GGC TCT G-3’). The reverse 284 
PCR primer used was 5’-AGA GTC GCG GCC GCT TAC TTG TAC A-3’. PCR fragments were 285 
digested with HindIII-HF (NEB R3104) and NotI-HF (NEB R3189) and ligated into pcDNA5/TO. The 286 
full set of pLenti-iA3i-HA constructs were previously described except the puromycin resistance gene 287 
was replaced with a hygromycin resistance gene [70]. Briefly, this is a lentiviral construct with an intron 288 
spanning the A3 gene with a C-terminal 3xHA tag, arranged in the antisense direction, which is expressed 289 
after reverse transcription and integration. This construct bypasses limitation of self-restriction by 290 
A3-mediated deamination of its own plasmid.  291 
EBV BORF2 (GenBank accession V01555.2) with a C-terminal 3x-FLAG (DYKDDDDK) tag 292 
and EBV BaRF1 (Genbank accession V01555.2) with a C-terminal 3x-HA (YPYDVPDYA) tag was 293 
previously described [32]. Other viral RNRs were subcloned with Phusion High Fidelity DNA 294 
Polymerase from previously described pCMV-3F vectors [32].  295 
KSHV ORF61 (GenBank accession U75698.1) was PCR amplified using primers 5’-NNN NGA 296 
ATT CGC CAC CAT GTC TGT CCG GAC ATT TTG T-3’ and 5’-NNN NGA ATT CGC CAC CAT 297 
GTC TGT CCG GAC ATT TTG T-3’, digested with EcoRI-HF (NEB R3101S) and NotI-HF, and ligated 298 
into pcDNA4 with a C-terminal 3x- FLAG. The same construct was PCR amplified using primers 299 
5’-NNN NGC GGC CGC GTC TGT CCG GAC ATT TTG T-3’ and 5’-NNN NTC TAG ATT ACT GAC 300 
AGA CCA GGC ACT C-3’, digested with NotI-HF and XbaI, and ligated into a similar pcDNA4 vector 301 
with N-terminal 3x- FLAG.  302 
HSV-1 UL39 (GenBank accession JN555585.1) was PCR amplified using primers 5’-NNN NGA 303 
TAT CCG CCA CCA TGG CCA GCC GCC CAG CC-3’ and 5’-NNN NGC GGC CGC CCC AGC GCG 304 
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CAG CT-3’, digested with EcoRV-HF (NEB R1395) and NotI-HF, and ligated into pcDNA4 (Invitrogen 305 
V102020) with a C-terminal 3x-FLAG [71]. The same construct was PCR amplified using primers 306 
5’-NNN NGC GGC CGC GGC CAG CCG CCC AGC CGC A-3’ and 5’-NNN NTC TAG ATT ACA 307 
GCG CGC AGC TCG TGC A-3’, digested with NotI-HF and XbaI (NEB R0145S), and ligated into a 308 
similar pcDNA4 vector with N-terminal 3x-FLAG.  309 
Human cell culture. Unless indicated, cell lines were derived from established lab collections. All cell 310 
cultures were supplemented with 10% heat-inactivated fetal bovine serum (Gibco 16140-063), 1x 311 
Pen-Strep (Thermo Fisher 15140122), and periodically tested for mycoplasma (Lonza MycoAlert PLUS 312 
LT07-710). No cell lines have ever been mycoplasma positive or previously treated. 293T and Vero cells 313 
were cultured in high glucose DMEM (Hyclone), U2OS cells were cultured in McCoy’s 5A media 314 
(Hyclone), and HeLa cells were cultured in RPMI 1640 (Corning).  315 
Co-immunoprecipitation experiments and immunoblots. Semi-confluent 293T cells were grown in 316 
6-well plates and transfected with plasmids and 0.6 µL TransIT-LT1 (Mirus 2304) per 100 ng DNA in 317 
100 µL serum-free Opti-MEM (Thermo Fisher 31985062). A titration series was performed to achieve 318 
roughly equivalent protein expression by immunoblot for the A3 panel and RNR homologue co-IP 319 
experiments. Growth medium was removed after 48 hrs and whole cells were harvested in 1 mL 320 
PBS-EDTA by pipetting. Cells were spun down, PBS-EDTA was removed, and cells were resuspended in 321 
300 µL of ice-cold lysis buffer [150 mM NaCl, 50mM Tris-HCl, 10% glycerol, 1% IGEPAL (Sigma 322 
I8896), Roche cOmplete EDTA-free protease inhibitor cocktail tablet (Roche 5056489001), pH 7.4]. 323 
Cells were vortexed vigorously and left on ice for 30 minutes, then sonicated for 5 seconds in an ice water 324 
bath. 30 µL of whole cell lysate was aliquoted for immunoblot. Lysed cells were spun down at 13,000 325 
rpm for 15 minutes to pellet debris and supernatant was added to clean tube with 25 µL resuspended 326 
anti-FLAG M2 Magnetic Beads (Sigma M8823) for overnight incubation at 4°C with gentle rotation. 327 
Beads were then washed three times in 700 µL of ice-cold lysis buffer. Bound protein was eluted in 30 µL 328 
of elution butter [0.15 mg/mL 3xFLAG peptide (Sigma F4799) in 150 mM NaCl, 50 mM Tris-HCl, 10% 329 
glycerol, 0.05% Tergitol, pH 7.4]. Proteins were analyzed by immunoblot and antibodies used include 330 
mouse anti-FLAG 1:5000 (Sigma F1804), mouse anti-tubulin 1:10,000 (Sigma T5168), and rabbit 331 
anti-HA 1:3000 (Cell Signaling C29F4). 332 
Generation and titration of HSV-1 viruses. The HSV-1 strains used were wild-type strain KOS1.1 [72], 333 
K26GFP [51], ICP6 deletion mutant ICP6Δ, and the ICP4 deletion mutant d120 [53]. HSV-1 infections 334 
were done at a multiplicity of infection of 5 PFU per cell, as previously described [73]. Titers of viral 335 
stocks were determined by plaque assay on either Vero cells (KOS1.1, K26GFP, and ICP6Δ) or 336 
ICP4-complementing E5-Vero cells [74]. 337 
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Immunofluorescence microscopy. For immunofluorescence imaging of transfected cells, approximately 338 
5x104 Vero, HeLa, or U2OS cells were plated on coverslips and after 24 hrs, transfected with 200 ng 339 
pcDNA4-RNR-3xFLAG, 200 ng pcDNA5/TO-A3-mCherry, or both. After 48 hrs, cells were fixed in 4% 340 
formaldehyde, permeabilized in 0.2% Triton X-100 in PBS for 10 minutes, washed three times for 5 341 
minutes in PBS, and incubated in blocking buffer (0.0028 M KH2PO4, 0.0072 M K2HPO4, 5% goat serum 342 
(Gibco), 5% glycerol, 1% cold water fish gelatin (Sigma), 0.04% sodium azide, pH 7.2) for 1 hr. Cells 343 
were then incubated in blocking buffer with primary mouse anti-Flag 1:1000 overnight at 4 ºC to detect 344 
FLAG-tagged RNRs. Cells were washed 3 times for 5 minutes with PBS, then incubated in secondary 345 
antibody goat anti-mouse AlexaFluor 488 1:1000 (Invitrogen A11001) diluted in blocking buffer for 2 hrs 346 
at room temperature in the dark. Cells were then counterstained with 1 µg/mL Hoechst 33342 for 10 347 
minutes, rinsed twice for 5 minutes in PBS, and once in sterile water. Coverslips were mounted on 348 
pre-cleaned slides (Gold Seal Rite-On) using 20-30 µL of mounting media (dissolve 1g n-propyl gallate 349 
(Sigma) in 40 mL glycerol overnight, add 0.35 mL 0.1M KH2PO4, then pH to 8-8.5 with K2HPO4, Q.S. to 350 
50mL with water). Slides were imaged on a Nikon Inverted Ti-E Deconvolution Microscope instrument 351 
and analyzed using NiS Elements.  352 
 For immunofluorescence imaging of HSV-1-infected cells, approximately 5x104 Vero, HeLa, or 353 
U2OS cells were plated on coverslips and after 24 hrs, transfected with 200 ng 354 
pcDNA5/TO-A3-mCherry. After 48 hours, cells were infected with HSV-1 K26GFP, HSV-1 KOS1.1, 355 
HSV-1 KOS1.1ΔICP6, or HSV-1 KOS1.1ΔICP4 at MOI 5. Cells were fixed in 4% formaldehyde 8 hours 356 
post-infection and then IF studies proceeded as above. Time course experiments were fixed at either 3, 6, 357 
9, or 12 hours post-infection. HSV-1 K26GFP experiments did not require primary or secondary antibody 358 
staining steps. Cells infected with HSV-1 KOS1.1 and mutants were incubated in primary antibody 359 
mouse anti-HSV-1 ICP27 H1113 (Santa Cruz sc69807) 1:1000 overnight at 4 ºC to detected 360 
HSV-1-infected cells. Secondary antibody staining, counterstaining with Hoechst, mounting, and imaging 361 
proceeded as above.  362 
 For quantification of A3 nuclear to cytoplasmic ratio, IF images were analysed using Fiji 363 
software to obtain mean fluorescence intensities (MFI) of nuclear compartments determined by Hoechst 364 
stain outline and cytoplasmic compartments determined by cell outline. MFI values were divided and 365 
plotted on Prism. Statistical analysis was performed using unpaired Student’s t-test.  366 
 367 
Acknowledgements 368 
We thank Sandy Weller, Neal Deluca, and Prashant Desai for HSV-1 strains, M. Sanders and staff at the 369 
University of Minnesota Imaging Center for assistance with fluorescence microscopy, J. Becker for 370 
assistance with confocal microscopy, D. Ebrahimi for bioinformatics analyses of A3 expression in 371 
 13 
different cell types, and P. Southern for thoughtful comments.  372 
 373 
Author Contributions 374 
Conceptualization, AZC, SAR, and RSH; Investigation, AZC, SNM, and CA; Resources, AZC, CJB, and 375 
SAR; Software, MCJ; Supervision, LF, CJB, SAR, and RSH; Validation, AZC, SNM, CA, JY-M, MB, 376 
GG, and VDO; Visualization, AZC; Writing – Original Draft, AZC and RSH;  Writing – Review & 377 
Editing, AZC, SNM, CA, JY-M, MCJ, MB, GG, VDO, LF, CJB, SAR, and RSH. 378 
 379 
Financial Disclosure Statement 380 
NIH training grants provided salary support for AZC (F30 CA200432 and T32 GM008244) and MCJ 381 
(T32 CA009138). JY-M was supported by Secretaría Nacional de Educación Superior, Ciencia, 382 
Tecnología e Innovación (SENESCYT). GG is a scholar under the Horizon2020 program (H2020 383 
MSCA-ITN-2015). V.D.O. is supported by Research Grants from the University of Turin (RILO18) and 384 
from the Italian Ministry of Education, University and Research – MIUR (PRIN 2015, 2015RMNSTA). 385 
RSH is the Margaret Harvey Schering Land Grant Chair for Cancer Research, a Distinguished McKnight 386 
University Professor, and an Investigator of the Howard Hughes Medical Institute. The funders had no 387 
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 388 
 389 
Competing Interests 390 
I have read the journal’s policy and the authors of this manuscript have the following competing interest: 391 
RSH is a co-founder, shareholder, and consultant of ApoGen Biotechnologies Inc. The other authors have 392 
declared that no competing interests exist. 393 
 394 
Correspondence and requests for materials should be addressed to RSH (rsh@umn.edu).  395 
 14 
References 396 
1. Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al. Human 397 
Herpesviruses: Biology, Therapy, and Immunoprophylaxis. In: Arvin A, Campadelli-Fiume G, 398 
Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human Herpesviruses: Biology, 399 
Therapy, and Immunoprophylaxis. Cambridge2007. 400 
2. Tzellos S, Farrell PJ. Epstein-barr virus sequence variation-biology and disease. Pathogens. 401 
2012;1(2):156-74. 402 
3. Grinde B. Herpesviruses: latency and reactivation - viral strategies and host response. J Oral 403 
Microbiol. 2013;5. 404 
4. Preston CM, Efstathiou S. Molecular basis of HSV latency and reactivation. In: Arvin A, 405 
Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human 406 
Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge2007. 407 
5. Jones C. Herpes simplex virus type 1 and bovine herpesvirus 1 latency. Clin Microbiol Rev. 408 
2003;16(1):79-95. 409 
6. Koyuncu OO, MacGibeny MA, Enquist LW. Latent versus productive infection: the alpha 410 
herpesvirus switch. Future Virol. 2018;13(6):431-43. 411 
7. Reddehase MJ, Lemmermann NAW. Cellular reservoirs of latent cytomegaloviruses. Med 412 
Microbiol Immunol. 2019. 413 
8. Aneja KK, Yuan Y. Reactivation and Lytic Replication of Kaposi's Sarcoma-Associated 414 
Herpesvirus: An Update. Front Microbiol. 2017;8:613. 415 
9. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic 416 
characteristics associated with infection. Rev Med Virol. 2010;20(4):202-13. 417 
10. Razonable RR, Humar A, Practice ASTIDCo. Cytomegalovirus in solid organ transplantation. 418 
Am J Transplant. 2013;13 Suppl 4:93-106. 419 
11. Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol. 420 
2006;1:273-96. 421 
 15 
12. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 422 
2015;235(2):288-97. 423 
13. Britt W. Virus entry into host, establishment of infection, spread in host, mechanisms of tissue 424 
damage. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., 425 
editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge2007. 426 
14. Paludan SR, Bowie AG, Horan KA, Fitzgerald KA. Recognition of herpesviruses by the innate 427 
immune system. Nat Rev Immunol. 2011;11(2):143-54. 428 
15. Simon V, Bloch N, Landau NR. Intrinsic host restrictions to HIV-1 and mechanisms of viral 429 
escape. Nat Immunol. 2015;16(6):546-53. 430 
16. Harris RS, Dudley JP. APOBECs and virus restriction. Virology. 2015;479-480:131-45. 431 
17. Malim MH, Emerman M. HIV-1 accessory proteins--ensuring viral survival in a hostile 432 
environment. Cell Host Microbe. 2008;3(6):388-98. 433 
18. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 434 
infection and is suppressed by the viral Vif protein. Nature. 2002;418(6898):646-50. 435 
19. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA 436 
deamination mediates innate immunity to retroviral infection. Cell. 2003;113(6):803-9. 437 
20. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. A second human antiretroviral factor, 438 
APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 2004;23(12):2451-8. 439 
21. Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, et al. 440 
APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology. 2005;2:32. 441 
22. Dang Y, Wang X, Esselman WJ, Zheng YH. Identification of APOBEC3DE as another 442 
antiretroviral factor from the human APOBEC family. J Virol. 2006;80(21):10522-33. 443 
23. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by 444 
APOBEC3G. Science. 2004;303(5665):1829. 445 
 16 
24. Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. Extensive editing of 446 
both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc 447 
Natl Acad Sci U S A. 2005;102(23):8321-6. 448 
25. Esnault C, Heidmann O, Delebecque F, Dewannieux M, Ribet D, Hance AJ, et al. APOBEC3G 449 
cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature. 450 
2005;433(7024):430-3. 451 
26. Chiu YL, Witkowska HE, Hall SC, Santiago M, Soros VB, Esnault C, et al. High-molecular-mass 452 
APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A. 453 
2006;103(42):15588-93. 454 
27. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, et al. Human 455 
papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase 456 
APOBEC3B. MBio. 2014;5(6). 457 
28. Vartanian JP, Guetard D, Henry M, Wain-Hobson S. Evidence for editing of human 458 
papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science. 459 
2008;320(5873):230-3. 460 
29. Peretti A, Geoghegan EM, Pastrana DV, Smola S, Feld P, Sauter M, et al. Characterization of BK 461 
Polyomaviruses from Kidney Transplant Recipients Suggests a Role for APOBEC3 in Driving 462 
In-Host Virus Evolution. Cell Host Microbe. 2018;23(5):628-35 e7. 463 
30. Verhalen B, Starrett GJ, Harris RS, Jiang M. Functional Upregulation of the DNA Cytosine 464 
Deaminase APOBEC3B by Polyomaviruses. J Virol. 2016;90(14):6379-86. 465 
31. Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, Logue E, et al. Deaminase-466 
independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog. 467 
2009;5(5):e1000439. 468 
32. Cheng AZ, Yockteng-Melgar J, Jarvis MC, Malik-Soni N, Borozan I, Carpenter MA, et al. 469 
Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity. Nat 470 
Microbiol. 2019;4(1):78-88. 471 
 17 
33. Martinez T, Shapiro M, Bhaduri-McIntosh S, MacCarthy T. Evolutionary effects of the 472 
AID/APOBEC family of mutagenic enzymes on human gamma-herpesviruses. Virus Evol. 473 
2019;5(1):vey040. 474 
34. Torrents E. Ribonucleotide reductases: essential enzymes for bacterial life. Front Cell Infect 475 
Microbiol. 2014;4:52. 476 
35. Iyer LM, Aravind L, Koonin EV. Common origin of four diverse families of large eukaryotic 477 
DNA viruses. J Virol. 2001;75(23):11720-34. 478 
36. Sakowski EG, Munsell EV, Hyatt M, Kress W, Williamson SJ, Nasko DJ, et al. Ribonucleotide 479 
reductases reveal novel viral diversity and predict biological and ecological features of unknown 480 
marine viruses. Proc Natl Acad Sci U S A. 2014;111(44):15786-91. 481 
37. Zhao Y, Temperton B, Thrash JC, Schwalbach MS, Vergin KL, Landry ZC, et al. Abundant 482 
SAR11 viruses in the ocean. Nature. 2013;494(7437):357-60. 483 
38. Cohen D, Adamovich Y, Reuven N, Shaul Y. Hepatitis B virus activates deoxynucleotide 484 
synthesis in nondividing hepatocytes by targeting the R2 gene. Hepatology. 2010;51(5):1538-46. 485 
39. Kitab B, Satoh M, Ohmori Y, Munakata T, Sudoh M, Kohara M, et al. Ribonucleotide reductase 486 
M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-487 
dependent proteasomal degradation. J Biol Chem. 2019;294(15):5759-73. 488 
40. Langelier Y, Bergeron S, Chabaud S, Lippens J, Guilbault C, Sasseville AM, et al. The R1 489 
subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or 490 
upstream of, caspase-8 activation. J Gen Virol. 2002;83(Pt 11):2779-89. 491 
41. Dufour F, Sasseville AM, Chabaud S, Massie B, Siegel RM, Langelier Y. The ribonucleotide 492 
reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNFalpha- and 493 
FasL-induced apoptosis by interacting with caspase-8. Apoptosis. 2011;16(3):256-71. 494 
42. Huang Z, Wu SQ, Liang Y, Zhou X, Chen W, Li L, et al. RIP1/RIP3 binding to HSV-1 ICP6 495 
initiates necroptosis to restrict virus propagation in mice. Cell Host Microbe. 2015;17(2):229-42. 496 
 18 
43. Mocarski ES, Guo H, Kaiser WJ. Necroptosis: The Trojan horse in cell autonomous antiviral host 497 
defense. Virology. 2015;479-480:160-6. 498 
44. Kwon KM, Oh SE, Kim YE, Han TH, Ahn JH. Cooperative inhibition of RIP1-mediated NF-499 
kappaB signaling by cytomegalovirus-encoded deubiquitinase and inactive homolog of cellular 500 
ribonucleotide reductase large subunit. PLoS Pathog. 2017;13(6):e1006423. 501 
45. Mack C, Sickmann A, Lembo D, Brune W. Inhibition of proinflammatory and innate immune 502 
signaling pathways by a cytomegalovirus RIP1-interacting protein. Proc Natl Acad Sci U S A. 503 
2008;105(8):3094-9. 504 
46. Lackey L, Law EK, Brown WL, Harris RS. Subcellular localization of the APOBEC3 proteins 505 
during mitosis and implications for genomic DNA deamination. Cell Cycle. 2013;12(5):762-72. 506 
47. Salamango DJ, McCann JL, Demir O, Brown WL, Amaro RE, Harris RS. APOBEC3B Nuclear 507 
Localization Requires Two Distinct N-Terminal Domain Surfaces. J Mol Biol. 508 
2018;430(17):2695-708. 509 
48. Salamango DJ, Becker JT, McCann JL, Cheng AZ, Demir O, Amaro RE, et al. APOBEC3H 510 
Subcellular Localization Determinants Define Zipcode for Targeting HIV-1 for Restriction. Mol 511 
Cell Biol. 2018;38(23). 512 
49. Muckenfuss H, Hamdorf M, Held U, Perkovic M, Lower J, Cichutek K, et al. APOBEC3 proteins 513 
inhibit human LINE-1 retrotransposition. J Biol Chem. 2006;281(31):22161-72. 514 
50. Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, Moran JV, et al. Cellular 515 
inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci U S A. 516 
2006;103(23):8780-5. 517 
51. Desai P, Person S. Incorporation of the green fluorescent protein into the herpes simplex virus 518 
type 1 capsid. J Virol. 1998;72(9):7563-8. 519 
52. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can 520 
compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization 521 
of an ICP6 deletion mutant. Virology. 1988;166(1):41-51. 522 
 19 
53. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of 523 
herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J 524 
Virol. 1985;56(2):558-70. 525 
54. Desai P, Ramakrishnan R, Lin ZW, Osak B, Glorioso JC, Levine M. The RR1 gene of herpes 526 
simplex virus type 1 is uniquely trans activated by ICP0 during infection. J Virol. 527 
1993;67(10):6125-35. 528 
55. Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of multiple 529 
epstein-barr virus strains in asymptomatic carriers. J Virol. 2003;77(3):1840-7. 530 
56. Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer 531 
Biol. 2014;26:60-8. 532 
57. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. Defining 533 
APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol. 534 
2009;83(18):9474-85. 535 
58. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an 536 
enzymatic source of mutation in breast cancer. Nature. 2013;494(7437):366-70. 537 
59. Chakraborty S, Veettil MV, Chandran B. Kaposi's Sarcoma Associated Herpesvirus Entry into 538 
Target Cells. Front Microbiol. 2012;3:6. 539 
60. Blasig C, Zietz C, Haar B, Neipel F, Esser S, Brockmeyer NH, et al. Monocytes in Kaposi's 540 
sarcoma lesions are productively infected by human herpesvirus 8. J Virol. 1997;71(10):7963-8. 541 
61. Wu W, Vieira J, Fiore N, Banerjee P, Sieburg M, Rochford R, et al. KSHV/HHV-8 infection of 542 
human hematopoietic progenitor (CD34+) cells: persistence of infection during hematopoiesis in 543 
vitro and in vivo. Blood. 2006;108(1):141-51. 544 
62. Kim IJ, Flano E, Woodland DL, Lund FE, Randall TD, Blackman MA. Maintenance of long term 545 
gamma-herpesvirus B cell latency is dependent on CD40-mediated development of memory B 546 
cells. J Immunol. 2003;171(2):886-92. 547 
 20 
63. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance 548 
of foreign DNA from human cells. Nat Struct Mol Biol. 2010;17(2):222-9. 549 
64. Thielen BK, McNevin JP, McElrath MJ, Hunt BV, Klein KC, Lingappa JR. Innate immune 550 
signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived 551 
cells through expression of APOBEC3A isoforms. J Biol Chem. 2010;285(36):27753-66. 552 
65. Nicoll MP, Proenca JT, Efstathiou S. The molecular basis of herpes simplex virus latency. 553 
2012;36(3):684-705. 554 
66. Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus 555 
entry. FEBS J. 2009;276(24):7228-36. 556 
67. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. 557 
Nucleic Acids Res. 2004;32(5):1792-7. 558 
68. Bouckaert R, Heled J, Kuhnert D, Vaughan T, Wu CH, Xie D, et al. BEAST 2: a software 559 
platform for Bayesian evolutionary analysis. PLoS Comput Biol. 2014;10(4):e1003537. 560 
69. Larue RS, Lengyel J, Jonsson SR, Andresdottir V, Harris RS. Lentiviral Vif degrades the 561 
APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. 562 
J Virol. 2010;84(16):8193-201. 563 
70. Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, et al. The DNA cytosine 564 
deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv. 565 
2016;2(10):e1601737. 566 
71. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, et al. Vif hijacks CBF-beta to 567 
degrade APOBEC3G and promote HIV-1 infection. Nature. 2011;481(7381):371-5. 568 
72. Hughes RG, Jr., Munyon WH. Temperature-sensitive mutants of herpes simplex virus type 1 569 
defective in lysis but not in transformation. J Virol. 1975;16(2):275-83. 570 
73. Park D, Lalli J, Sedlackova-Slavikova L, Rice SA. Functional comparison of herpes simplex 571 
virus 1 (HSV-1) and HSV-2 ICP27 homologs reveals a role for ICP27 in virion release. J Virol. 572 
2015;89(5):2892-905. 573 
 21 
74. DeLuca NA, Schaffer PA. Physical and functional domains of the herpes simplex virus 574 
transcriptional regulatory protein ICP4. J Virol. 1988;62(3):732-43. 575 
  576 
 22 
Figure Legends 577 
 578 
Fig 1. Herpesvirus ribonucleotide reductases conservation. 579 
(A) Amino acid sequences from ribonucleotide reductase large subunits were aligned using Multiple 580 
Sequence Comparison by Log-Expectation (MUSCLE) and phylogeny was constructed using 581 
neighbor-joining tree without distance corrections and scaled for equal branch lengths (scale bar = 1). 582 
Shaded boxes indicate herpesvirus subfamilies, which group closely to established phylogenetic trees. 583 
Protein names for human herpesvirus ribonucleotide reductase large and small subunits shown on the 584 
right.  585 
(B) Schematic of representative RNR large subunit polypeptides from α-, β-, and γ-herpesviruses with 586 
conserved core sequences (colored) and unique N- and C-terminal extensions (gray). Diagram is 587 
approximately to scale with a ~190 amino acid portion of HSV-1 ICP6 omitted to fit the figure. Scale bar 588 
is 100 amino acids.  589 
 590 
Fig 2. EBV BORF2 relocalizes A3B and A3A. 591 
Representative images of U2OS cells transfected with either A3-mCherry or BORF2-FLAG constructs. 592 
Cells were fixed 48 hours post-transfection, permeabilized, and stained with anti-FLAG antibody and 593 
Hoechst. A3 localization was compared in the presence and absence of EBV BORF2-FLAG 594 
co-transfection. 595 
 596 
Fig 3. KSHV ORF61 relocalizes A3B and A3A. 597 
(A) Co-immunoprecipitation of transfected KSHV ORF61-FLAG with the indicated A3-HA constructs in 598 
293T cells. Cells were lysed 48 hours post-transfection for anti-FLAG pulldown and resulting proteins 599 
were analyzed by immunoblot. EBV FLAG-BORF2 transfected with A3B and A3G were used as positive 600 
and negative co-IP controls, respectively.  601 
(B) Representative images of U2OS cells transfected with either A3-mCherry or FLAG-RNR constructs. 602 
Cells were fixed 48 hours post-transfection, permeabilized, and stained with anti-FLAG antibody and 603 
Hoechst. Co-transfection with A3B-mCherry and EBV BORF2-FLAG was used as positive controls for 604 
relocalization from nuclear to cytoplasmic aggregates. A3 localization was compared in the presence and 605 
absence of KSHV ORF61-FLAG co-transfection. 606 
 607 
Fig 4. HSV-1 ICP6 binds and relocalizes A3B and A3A. 608 
(A) Co-immunoprecipitation of transfected HSV-1 FLAG-ICP6 with the indicated A3-HA constructs in 609 
293T cells. Cells were lysed 48 hours post-transfection for anti-FLAG pulldown and resulting proteins 610 
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were analyzed by immunoblot. EBV FLAG-BORF2 transfected with A3B and A3G were used as positive 611 
and negative co-IP controls, respectively.  612 
(B) Representative images of U2OS cells transfected with either A3-mCherry or FLAG-RNR constructs. 613 
Cells were fixed 48 hours post-transfection, permeabilized, and stained with anti-FLAG antibody and 614 
Hoechst. Co-transfection with A3B-mCherry and EBV FLAG-BORF2 was used as positive controls for 615 
relocalization from nuclear to cytoplasmic aggregates. A3 localization was compared in the presence and 616 
absence of HSV-1 FLAG- ICP6 co-transfection.  617 
 618 
Fig 5. HSV-1 infection relocalizes A3B and A3A. 619 
Representative images of U2OS cells transfected with A3-mCherry constructs, followed by mock or 620 
HSV-1 K26GFP infection 48 hours post-transfection. Cells were fixed 8 hpi and stained with Hoechst, 621 
then imaged directly. The viral capsid protein VP26 is tagged with GFP which marks infected cells.  622 
 623 
Fig 6. A3B and A3A relocalization is dependent on HSV-1 ICP6. 624 
(A) Representative images of Vero cells transfected with A3-mCherry constructs, followed by mock, 625 
wild-type HSV-1 KOS1.1, or HSV-1 KOS1.1ΔICP6 infection 48 hours post-transfection. Cells were 626 
fixed 8 hours after HSV-1 infection, permeabilized, and stained with anti-ICP27 antibody to mark 627 
infected cells and Hoechst. 628 
(B) Representative images from an experiment similar to that described in panel A, except using U2OS 629 
cells and the mutant virus HSV-1 KOS1.1ΔICP4.  630 
 631 
 632 
  633 
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Supporting Information 634 
Supplementary Fig 1. EBV BORF2 relocalizes A3B and A3A. 635 
Representative immunofluorescence microscopy images of Vero cells transfected with either A3-mCherry 636 
or EBV BORF2-FLAG constructs. Cells were fixed 48 hours post-transfection, permeabilized, and 637 
stained with anti-FLAG antibody and Hoechst to stain the nuclear compartment.  638 
 639 
Supplementary Fig 2. HSV-1 infection relocalizes A3B and A3A. 640 
Representative images of Vero cells transfected with A3-mCherry constructs, followed by mock or 641 
HSV-1 K26GFP infection 48 hours post-transfection. Cells were fixed 8 hpi and then imaged directly. 642 
The viral capsid protein VP26 is tagged with GFP to mark infected cells.  643 
 644 
Supplementary Fig 3. Time course of HSV-1-mediated relocalization of A3B and A3A. 645 
Representative images of U2OS cells transfected with A3-mCherry constructs, followed by mock or 646 
HSV-1 KOS1.1 infection 48 hours post-transfection. Cells were fixed at either 3, 6, 9, or 12 hpi and 647 
stained with anti-ICP27 antibody to mark infected cells and Hoechst to stain the nuclear compartment.  648 
 649 
Supplementary Fig 4. A3B and A3A localization is altered by HSV-1 infection. 650 
Quantification of A3 localization patterns with or without HSV-1 infection by dividing the mean 651 
fluorescence intensity of the nuclear and cytoplasmic compartments. Data points are pooled evenly from 652 
immunofluorescence microscopy images shown in Figs. 5 and 6. Statistical analysis was performed using 653 
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